Corporate Profile for IntraBiotics Pharmaceuticals, Inc., dated Aug. 13, 1999.--(BUSINESS WIRE)-- The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Aug. 13, 1999
Company Name: IntraBiotics Pharmaceuticals, Inc.
Address: 1255 Terra Bella Avenue
Mountain View, CA 94043
Main Telephone
Number: 650/526-6800
Internet Home
Page Address
(URL) www.intrabiotics.com
Chief Executive
Officer: Kenneth J. Kelley
Chief Financial
Officer: Peter S. Garcia
Investor Relations
Contact: Kenneth J. Kelley
Business number: 650/526-6800
E-mail address: info@intrabiotics.com
Public Relations
Contact: Kenneth J. Kelley
Business number: 650/526-6800
E-mail address: info@intrabiotics.com
Industry: Biotech
Company description: IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company developing novel antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. and antifungal antifungal /an·ti·fun·gal/ (-fung´gal) 1. destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections. 2. an agent that so acts. pharmaceuticals for the treatment and prevention of serious infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , including the phenomenon of multi-drug resistant microbes. The company's technology consists of several distinct chemical classes of antibacterials or antifungals. The company has two products entering into Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the and several other drug candidates in earlier stage research and development. Additional information on the company can be accessed through the company's web site a www.intrabiotics.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion